Drug class in one race
PD-L1 / TIGIT drugs for Non-Small Cell Lung Cancer
2 tracked PD-L1 / TIGIT drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the PD-L1 / TIGIT page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 Phase 1/2
Head-to-head evidence: HB0036 vs HLX301